Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.19 USD

11.19
5,306,165

+0.75 (7.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $11.24 +0.05 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

by Zacks Equity Research

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -67.74% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Petrobras (PBR) Report Q2 Earnings Beat on Output Gains?

by Zacks Equity Research

Petrobras (PBR) beat the Zacks Consensus Estimate for earnings just once in the last four quarters and missed in the other three.

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

by Zacks Equity Research

Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

by Zacks Equity Research

Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.

Kinjel Shah headshot

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

by Kinjel Shah

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

by Zacks Equity Research

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

by Zacks Equity Research

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Iovance (IOVA) Might Surprise This Earnings Season

by Zacks Equity Research

Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

by Zacks Equity Research

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

by Zacks Equity Research

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi

by Zacks Equity Research

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance

by Zacks Equity Research

Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Stellar Returns

by Tirthankar Chakraborty

Universal Stainless & Alloy Products (USAP), Lakeland Industries (LAKE), NGL Energy Partners (NGL) and Iovance Biotherapeutics (IOVA) have been selected as the breakout stocks for today.